CAPR Stock Analysis: Buy, Sell, or Hold?
CAPR - Capricor Therapeutics Inc
$29.58
0.57 (1.96%)
▲
5d:
-0.77%
30d:
-15.49%
90d:
+3.75%
BUY
MODERATE Confidence
Analysis Updated: May 21, 2026 12:00 AM ET
Earnings: May 20, 2026
0d
Smart Money Accumulation
None View Scanner →
Strength: 7.6/10
Get Alerted When CAPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
32 traders called CAPR this week
91% bullish • 3 bearish
91% bullish • 3 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CAPR shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CAPR shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CAPR is currently trading at $29.58, which is considered oversold relative to its 30-day fair value range of $30.11 to $35.02. From a valuation perspective, the stock is trading at a discount (Forward PE: -38.7) compared to its historical average (133.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAPR is in a strong downtrend. Immediate support is located at $26.60, while resistance sits at $32.55.
Market Sentiment: CAPR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $54.11 (+82.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CAPR is in a strong downtrend. Immediate support is located at $26.60, while resistance sits at $32.55.
Market Sentiment: CAPR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $54.11 (+82.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$30.11 -
$35.02
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 82.9% below Wall St target ($54.11)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$30.11 -
$35.02
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.73
(12.6%)
Support & Resistance Levels
Support Level
$26.60
Resistance Level
$32.55
Current Trend
Strong Downtrend
Technical data as of
May 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-38.73
Wall Street Target
$54.11
(+82.9%)
Revenue Growth (YoY)
-7.9%
PE vs Historical
-38.7 vs 133.6
CHEAP
Share & Embed Analysis
Last updated: May 21, 2026 8:29 PM ET
Data refreshes hourly during market hours. Next update: 9:29 PM
Data refreshes hourly during market hours. Next update: 9:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Karimah Es Sabar
SELL
7529 shares
2026-04-02
Karimah Es Sabar
SELL
53735 shares
2026-04-01
Anthony Bergmann
SELL
25000 shares
2026-03-31
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 51 HOLD |
Advanced CAPR Option Strategies
Professional options setups generated by AI based on today's CAPR price and gamma walls.
